Accedi
Accedi
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrati
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

FATE THERAPEUTICS, INC.

(FATE)
  Rapporto
Tempo differito Nasdaq  -  22:00:00 03/02/2023
6.870 USD   +0.59%
24/01Fate Therapeutics, Inc.: giudizio non più positivo da HC Wainwright
MM
09/01Fate Therapeutics, Inc.: Goldman Sachs ancora valutazione negativa
MM
06/01I piani di prioritizzazione della pipeline di Century Therapeutics indicano un calo dell'hype per le cellule Natural Killer, dice la ricerca Chardan.
MT
RiassuntoQuotazioniGraficiNotizieRatingCalendarioSocietąFinanzaConsensusRevisioniDerivatiFondi 
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su FATE THERAPEUTICS, INC.
25/01North American Morning Briefing: Microsoft -2-
09/01North American Morning Briefing: 'Soft Landing' -3-
06/01Century Therapeutics' Pipeline Prioritization Plans Indicate Declining Natural Killer C..
06/01Top Midday Decliners
06/01December Jobs Report Showing Easing Wage Pressures Lift US Equity Futures
06/01Top Premarket Decliners
06/01North American Morning Briefing: Stock Futures Soft as I..
06/01Fate Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Potential Securities Cla..
05/01Fate Therapeutics Inc: Termination of a Material Definitive Agreement, Costs Associated w..
05/01Fate Therapeutics, Inc. Expects to Terminate Mark Plavsic as Chief Technical Officer, E..
05/01Fate Therapeutics, Inc. Receives Notice of Termination from Janssen Biotech,Inc. of the..
05/01Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeli..
05/01Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeli..
04/01North American Morning Briefing: Futures Rise -2-
2022Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemothe..
2022Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemothe..
2022GT Biopharma, Fate Therapeutics Say Preclinical Data Shows Potential of New Approach to..
2022Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derive..
2022Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multi..
2022Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multi..
2022Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derive..
2022Fate Therapeutics Announces Clinical Safety and Activity Data of First-Ever iPSC-Derive..
2022Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derive..
2022Ono Exercises Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors Gen..
2022Fate Therapeutics Inc: Entry into a Material Definitive Agreement, Regulation FD Disclosu..
2022Fate Therapeutics, Inc. and Ono Pharmaceutical Co., Ltd. Enters into Letter Agreement i..
2022Fate Therapeutics Says ONO Pharmaceutical Exercises Option to Product Candidate for Sol..
2022Fate Therapeutics to Present at Upcoming Investor Conferences
2022Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted C..
2022Fate Therapeutics to Present at Upcoming Investor Conferences
2022Fate Therapeutics to Present at Upcoming Investor Conferences
2022Fate Therapeutics: Q3 Earnings Snapshot
2022FATE THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and ..
2022Fate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months ..
2022Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operation..
2022Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at..
2022Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at..
2022Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2022 Financial Res..
2022Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2022 Financial Res..
2022Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at..
2022Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at..
2022Fate Therapeutics to Participate at Upcoming September Investor Conferences
2022Fate Therapeutics to Participate at Upcoming September Investor Conferences
2022Insider Sell: Fate Therapeutics
2022Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8?? T ..
2022Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8&alph..
2022Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8&alph..
2022Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8aß T ..
2022Fate Therapeutics: Q2 Earnings Snapshot
2022FATE THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and ..
2022Fate Therapeutics: Reports Second Quarter 2022 Financial Results and Highlights Operation..
2022Fate Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months ..
2022Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operatio..
2022Earnings Flash (FATE) FATE THERAPEUTICS Reports Q2 Revenue $18.5M
2022Insider Sell: Fate Therapeutics
2022Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2022 Financial Re..
2022Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2022 Financial Re..
2022North American Morning Briefing: Stock Futures -2-
2022Insider Sell: Fate Therapeutics
2022Insider Sell: Fate Therapeutics
2022Fate Therapeutics: Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceutic..
2022Fate Therapeutics Appoints Brian Powl as Chief Commercial Officer
2022Fate Therapeutics Inc: Entry into a Material Definitive Agreement, Regulation FD Disclosu..
2022Fate Therapeutics Appoints Brian T. Powl as Chief Commercial Officer
2022Fate Therapeutics Appoints Brian T. Powl as Chief Commercial Officer
2022Fate Therapeutics, Inc. Appoints Brian T. Powl as Chief Commercial Officer
2022ONO Announces Expanded Collaboration with Fate Therapeutics on iPSC-derived CAR-T Cell ..
2022Fate Therapeutics Expands Collaboration with ONO Pharmaceutical for Solid Tumor Immunot..
2022Fate Therapeutics Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceuti..
2022Fate Therapeutics Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceuti..
2022Fate Therapeutics, Inc. Announces Expansion of Solid Tumor Collaboration with Ono Pharm..
2022Fate Therapeutics Inc: Change in Directors or Principal Officers, Submission of Matters t..
2022Fate Therapeutics Shares Tumble Amid Lower-Than-Average Trading Volume
2022Fate Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference
2022Fate Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference
2022Fate Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference
2022Fate Therapeutics to Present at Upcoming May Investor Conferences
2022Fate Therapeutics to Present at Upcoming May Investor Conferences
2022Fate Therapeutics to Present at Upcoming May Investor Conferences
2022FATE THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and ..
2022Fate Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, ..
2022Fate Therapeutics: Q1 Earnings Snapshot
2022Earnings Flash (FATE) FATE THERAPEUTICS Posts Q1 Revenue $18.4M
2022Fate Therapeutics Reports First Quarter 2022 Financial Results and Highlights Operation..
2022Insider Sell: Fate Therapeutics
2022Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2022 Financial Res..
2022Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2022 Financial Res..
2022Insider Sell: Fate Therapeutics
2022Insider Sell: Fate Therapeutics
2022Fate Therapeutics to Present at Upcoming March Investor Conferences
2022Fate Therapeutics: Reports Fourth Quarter and Full Year 2021 Financial Results and Highli..
2022Fate Therapeutics: Q4 Earnings Snapshot
2022FATE THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and ..
2022Fate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2..
2022Fate Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December ..
2022Earnings Flash (FATE) FATE THERAPEUTICS Posts Q4 Revenue $17.1M
2022Fate Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highl..
2022Fate Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highl..
2022Fate Therapeutics, Inc. Provides Earnings Guidance for the Year Ending December 31, 202..
2022Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 202..
Prossimo evento su FATE THERAPEUTICS, INC.